Piper Jaffray downgraded ISIS Pharmaceuticals (NASDAQ: ISIS) from Overweight to Neutral with a price target of $68.00 (from $81.00) telling ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE